A Sham-Controlled Study to Evaluate the Safety and Efficacy of a Smart, Self-Adjusting, Surgery-Free, Wearable Bladder Neuromodulation System for Overactive Bladder

Last updated: May 28, 2024
Sponsor: Avation Medical, Inc.
Overall Status: Terminated

Phase

N/A

Condition

Urinary Incontinence

Enuresis

Overactive Bladder

Treatment

Avation System

Sham Avation System

Clinical Study ID

NCT05381116
AMHOAB2101
  • Ages > 18
  • All Genders

Study Summary

This is a prospective, multi-center, sham-controlled study comparing the safety and effectiveness of the self-adjusting, surgery-free, wearable Active System to a Sham System on adult Subjects diagnosed with OAB.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male or female and 18 years of age or older at the time of enrollment

  2. Willing and capable of giving informed consent

  3. Willing and able to comply with all Study-related requirements and procedures

  4. Have been diagnosed or have symptoms of OAB for at least 3 months prior toenrollment

  5. Have an average of 11 or more voiding events and/or 3 or more incontinent events per 24-hour period in a 3-Day Bladder Diary(a minimum of 30 voiding events over the 3days measured by the Diary)

  6. If currently on medications that may affect their OAB symptoms, is on a stable dose (no new, discontinued, or change in dose) of all prescribed medications for at least 4 weeks prior to enrollment or throughout the Study

  7. Female Subjects of child-bearing potential must have a negative urine dip stickpregnancy test at baseline

Exclusion

Exclusion Criteria:

  1. Has been diagnosed with incontinence due to neurogenic bladder(stroke, CNS tumors,Parkinson's etc.)

  2. Have failed a third line treatment (PTNS, Botox or SNS) for their OAB because oflack of effectiveness within the 2 years prior to enrollment

  3. Have evidence of an uncontrolled active disruptive psychological or psychiatricdisorder or other known condition significant enough to impact perception of pain,compliance of intervention and/or ability to evaluate treatment outcomes, in theopinion of the Investigator

  4. Has or had a significant untreated substance use disorder or polysubstance usedisorder stemming from dependency-producing medications, alcohol, and/or illicitdrugs less than 6 months prior to enrollment

  5. Are planning to or have scheduled a surgery, for any condition, that would requirecatheterization, or a prolonged hospital stay and affect the ability to ambulate,use the toilet, or complete Therapy during the first 12 weeks of the Study

  6. Has symptoms of, been diagnosed, or being actively treated for benign prostatichyperplasia or prostate cancer (weak stream, straining, hesitancy, or intermittency)

  7. Have a pacemaker or implanted defibrillator

  8. Has a neurological disorder that affects the bladder or a diagnosis of interstitialcystitis, radiation cystitis, or fistulas

  9. Incontinence due to stress-predominant mixed urinary incontinence (greater that 60%of the time)or being actively treated for stress urinary incontinence(Diagnosed orby review of the Baseline 3-Day Bladder Diary)

  10. Has been diagnosed with or has symptoms of polyuria (>2500 cc urine output per day)

  11. Has urinary retention or incomplete bladder emptying

  12. Have a documented current or reoccurring Urinary Tract Infection (3 or more in themonths prior to enrollment)

  13. Have had Botox treatment for their OAB in the previous 8 months

  14. Have used TENS anywhere on the body within the last year for any reason oranticipated use of TENS within 12 weeks of enrollment in pelvic region, back or legsfor any reason

  15. Had PTNS treatment for OAB within 6 months prior to enrollment.

  16. Use of investigational drug/device Therapy, for any reason, within past 12 weeks

  17. Current use or implantation of an implanted device for treatment of their OAB orincontinence (including but not limited to sacral nerve stimulators)

  18. Participation in another clinical Study during the term of the Study

  19. Pregnant or planning to become pregnant during the Study. Female Subjects ofchildbearing potential who become pregnant during the Study will be withdrawn fromthe Study and will be asked to sign a separate pregnancy consent form to allow theInvestigator and Sponsor to follow up on the Subject's pregnancy and outcome

  20. Has scar tissue, metal, or another implant or a large tattoo that might interferewith Therapy

  21. Has a neurological disorder that causes abnormal sensations in the lower leg (lossof sensation or allodynia)

  22. Has a skin condition, for example allergic reaction, rash or open wounds, in thearea of where the Therapy Garment will be placed

Study Design

Total Participants: 125
Treatment Group(s): 2
Primary Treatment: Avation System
Phase:
Study Start date:
April 14, 2022
Estimated Completion Date:
July 01, 2023

Connect with a study center

  • Eclipse Clinical Research

    Tucson, Arizona 85745
    United States

    Site Not Available

  • Women's Health Institute

    Oak Lawn, Illinois 60453
    United States

    Site Not Available

  • Ochsner Medical Center

    New Orleans, Louisiana 70121
    United States

    Site Not Available

  • Regional Urology

    Shreveport, Louisiana 71106
    United States

    Site Not Available

  • Flourish Research

    San Antonio, Texas 78229
    United States

    Site Not Available

  • Tranquil Medical Rsearch

    Webster, Texas 77598
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.